Open interest: Calls 1,805 vs Puts 129 → very low put/call OI ratio (0.07) suggesting positioning skewed to calls.
Volume: today’s option volume is 0 (no put or call volume reported) → current session sentiment from flow is not informative.
Volatility: IV30 ~130% vs historical vol ~50% → options are priced for very large moves; expensive premium reduces attractiveness of chasing upside via options.
IV trend: short-term IV averages (5d ~136.6, 10d ~177.8) suggest elevated/unstable volatility regime.
Technical Summary
Sell
0
Buy
14
Positive Catalysts
is possible if support holds.
Neutral/Negative Catalysts
Momentum is bearish and still deteriorating (MACD negative and worsening).
Price remains below pivot resistance (1.807); rallies may be sold until that level is reclaimed.
Company fundamentals (latest reported quarter) show sharp YoY declines across revenue and earnings.
News provided appears sector/peer-related (Incyte) rather than a direct MacroGenics catalyst → limited event-driven upside signal.
Trading trends: hedge funds and insiders are reported neutral—no supportive accumulation signal.
No Intellectia proprietary buy triggers today (reduces confidence for an immediate entry for an impatient buyer).
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 72.839M, down -34.21% YoY → significant contraction.
Net income: 16.822M, down -70.13% YoY → profitability weakening sharply.
EPS: 0.27, down -70.00% YoY.
Gross margin: 84.09%, down -14.46% YoY → margin compression.
Overall: growth trends are negative (top-line decline + steep earnings drop), which undermines a “buy now” thesis without a clear catalyst.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so a recent trend assessment cannot be confirmed from this dataset.
Wall Street-style pros (typical): biotech optionality and potential pipeline/event upside.
Wall Street-style cons (dominant given provided data): deteriorating YoY financial trends and lack of identified near-term catalyst/supportive rating momentum in the provided inputs.
Wall Street analysts forecast MGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGNX is 3 USD with a low forecast of 2 USD and a high forecast of 4 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast MGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGNX is 3 USD with a low forecast of 2 USD and a high forecast of 4 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
3 Hold
0 Sell
Hold
Current: 1.700
Low
2
Averages
3
High
4
Current: 1.700
Low
2
Averages
3
High
4
Barclays
NULL -> Overweight
initiated
$3
AI Analysis
2025-09-16
Reason
Barclays
Price Target
$3
AI Analysis
2025-09-16
initiated
NULL -> Overweight
Reason
Barclays initiated coverage of MacroGenics with an Overweight rating and $3 price target.
Barclays
Etzer Darout
Overweight
initiated
$3
2025-09-16
Reason
Barclays
Etzer Darout
Price Target
$3
2025-09-16
initiated
Overweight
Reason
Barclays analyst Etzer Darout assumed coverage of MacroGenics with an Overweight rating and $3 price target. The firm believes MGC026 could drive share upside in 2026 due to the shortcomings of the competitor B7H3 antibody drug conjugate programs.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MGNX
